Research seeks to understand how codeine sales restrictions will affect codeine consumers and health professionals.
In August this year, the TGA made the interim decision to move all OTC codeine medications to prescription-only medicines (Schedule 4). This interim decision was made on the basis of the above concerns regarding risk of dependence and side-effects with codeine use and the known availability of safer OTC products.
There are important benefits and impacts to consider with rescheduling codeine to prescription-only. Based on the public submissions provided to the TGA as part of this process, key concerns